Use of an isoform of IL-18BP that lacks the ability to bind to IL-18 or neutralize it and induces nuclear translocation of STAT2, for the manufacture of a medicament for the treatment and / or prevention of an inflammatory disease neurological, wherein said isoform of IL-18BP is characterized by an amino acid sequence containing the 36 carboxyterminal amino acids of IL-18BPb (SEQ ID No. 1) and IL-18BPd (SEQ ID No. 2) and which is selected from the group consisting of: a) a polypeptide comprising SEQ ID. No. 1； b) a polypeptide comprising amino acids 29 to 113 of SEQ ID. No. 1； c) a polypeptide comprising amino acids 78 to 113 of SEQ ID. No. 1； d) a polypeptide comprising SEQ ID. No. 2； e) a polypeptide comprising amino acids 29 to 161 of SEQ ID. No. 2； f) a mutein of one of a), b), d) or e), wherein the amino acid sequence has an identity of at least 75%, 80%, 85%, 90%, 95%, 96%, 97 %, 98% or 99% with at least one of the sequences of a) to e)； g) a mutein of one of a) to e) that is encoded by a DNA sequence that hybridizes with the complement of the native DNA sequence encoding any of a) to e) under moderately stringent conditions or under very stringent conditions； h) a mutein of one from a) to e) wherein any change in the amino acid sequence is a conservative amino acid substitution of the amino acid sequences from a) to e)； i) a fusion salt or protein, functional derivative, active fraction or circular permutation derivative of any one of a) to h), muteins, salts, fusion proteins, functional derivatives, active fractions or circular permutation derivatives of f) ai) retain a similar or even better biological activity than that of the form that occurs in nature.Utilización de una isoforma de IL-18BP que carece de la capacidad de fijarse a la IL-18 o de neutralizarla y que induce la translocación nuclear de STAT2, para la fabricación de un medicamento para el tratamiento y/o la prevención de una enfermedad inflamatoria neurológica, en donde dicha isoforma de IL-18B
